TRAW Stock Analysis: Buy, Sell, or Hold?
TRAW - Traws Pharma, Inc. Common Stock
$0.77
-0.04 (-5.34%)
▼
5d:
-7.73%
30d:
-45.94%
90d:
-53.75%
HOLD
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When TRAW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TRAW shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TRAW shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TRAW is currently trading at $0.77, which is considered oversold relative to its 30-day fair value range of $0.83 to $1.43.
Technical Outlook: Technically, TRAW is in a downtrend. The price is currently testing key support at $1.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.00 (+30.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TRAW is in a downtrend. The price is currently testing key support at $1.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $1.00 (+30.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.83 -
$1.43
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 30.3% below Wall St target ($1.00)
- CAUTION: Recommendation downgraded due to -7.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.43
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.31
Resistance Level
$1.72
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.39
Wall Street Target
$1.00
(+30.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 10:43 PM ET
Data refreshes hourly during market hours. Next update: 11:43 PM
Data refreshes hourly during market hours. Next update: 11:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRAW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |